Detalhe da pesquisa
1.
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Biochem Soc Trans
; 39(2): 456-9, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21428919
2.
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Mol Cancer Ther
; 6(8): 2209-19, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17699718
3.
A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055.
Br J Pharmacol
; 174(16): 2652-2661, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28556895
4.
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Oncotarget
; 8(41): 69219-69236, 2017 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29050199
5.
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
Oncotarget
; 7(15): 20773-87, 2016 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26980748
6.
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Mol Cancer Ther
; 14(11): 2441-51, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26351323
7.
Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.
Mol Imaging Biol
; 16(3): 421-30, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24249640
8.
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Cancer Chemother Pharmacol
; 71(4): 1021-32, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23355042
9.
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
Cancer Res
; 72(7): 1804-13, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22271687
10.
The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Clin Cancer Res
; 15(21): 6619-29, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843666
11.
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Mol Oncol
; 3(3): 248-61, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19393585
12.
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Hum Mol Genet
; 14(9): 1153-60, 2005 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15772091